Replimune Group, Inc.
Financial highlights
| Metric | FY 03/31/26 | FY 03/31/25 | FY 03/31/24 | FY 03/31/23 | FY 03/31/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$319.9 | -$261.6 | -$234.8 | -$177.1 | -$118.3 |
| Net income | -$313.9 | -$247.3 | -$215.8 | -$174.3 | -$118.0 |
| Cash Flow Statement | |||||
| Free cash flow | -$284.6 | -$198.9 | -$191.1 | -$130.3 | -$84.5 |
Shares outstanding 94.2M · Free float 83.2%
Annual filing data through FY ended March 31, 2026; float as of October 4, 2026.
Coverage
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
July 2, 2026
Small-Cap Signal
AI Infrastructure Capital Floods In While Biotech Trials Split
June 30, 2026
Filings Beige Book
Input Costs Squeeze Margins Even as Demand Holds Firm
June 29, 2026
Economy Survey
Credit Lines and Coupon Math Anchor Week's Economy Commentary